3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
3
Completed
1
Sponsor Class
INDUSTRY
2
NIH
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Neoplasm Metastasis
2
Carcinosarcoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms by Site
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Endometrioid
1
Interventions
pembrolizumab
29
Carboplatin
27
Specimen Handling
21
durvalumab
20
Pemetrexed
18
Cisplatin
17
Paclitaxel
16
atezolizumab
15
Nivolumab
15
Magnetic Resonance Spectroscopy
15
osimertinib
11
Radiosurgery
11
Radiotherapy
10
Immunoglobulin G
10
Etoposide
10
Docetaxel
10
Disulfides
10
Radiation
9
Taxes
8
Gemcitabine
8
Biopsy
8
Blood Specimen Collection
7
Standard of Care
6
Practice Guidelines as Topic
6
Ipilimumab
6
Surveys and Questionnaires
5
Platinum
5
Bronchoscopy
5
Bevacizumab
5
Ramucirumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lung Neoplasms
×
ceralasertib
×
Clear all
NCT06732401
2026-05-13
CLEAR
National Cancer Institute (NCI)
Phase 3
Active not recruiting
630 enrolled
NCT05450692
2026-04-16
LATIFY
AstraZeneca
Phase 3
Active not recruiting
594 enrolled
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled